Navigation Links
UT Southwestern researchers find protein that might be key to cutting cancer cells' blood supply
Date:5/11/2011

and is not found in the smooth muscle cells that make up the outside of the vessels.

The UT Southwestern scientists also discovered that Rasip1 and a protein binding partner are both required for blood vessels to form channels through which blood can flow, she said.

Most approaches to therapies aimed at blocking blood vessel formation have focused on growth factors that occur outside the cell rather than intrinsic cellular growth factors like Rasip1, Dr. Cleaver said.

"Although this is still a mouse study, we feel that future studies of Rasip1 and the molecular processes under its control hold great promise to provide tools and models for advancing clinical therapies aimed at blocking vessel formation in tumors," she said.

The researchers now plan to look for drugs that block Rasip1 in order to eventually develop strategies to stop the growth of functional blood vessels and starve cancerous tumors, she said.


'/>"/>

Contact: Deborah Wormser
deborah.wormser@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. UT Southwestern research reveals how cancer-driving enzyme works
2. Signaling path in brain may prevent that Im full message, UT Southwestern scientists discover
3. Team of scientists predicts continued death of forests in southwestern US due to climate change
4. UT Southwestern researchers uncover culprits in life-threatening clotting disorder
5. Alcohol consumers are becoming the norm, UT Southwestern analysis finds
6. UT Southwestern researchers find key step in bodys ability to make red blood cells
7. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
8. UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle
9. UT Southwestern researchers identify key molecular step to fighting off viruses
10. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
11. New brain nerve cells key to stress resilience, UT Southwestern researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... a mashup of monster movies, but palaeontologists have discovered evidence ... killing that took place 4 million years ago. ... careful, forensic-style analysis of bite marks on an otherwise well-preserved ... reconstructed the events that led to the death of the ...
... years of satellite data have found that the amount of ... the last three decades. Most of the increase has occurred ... increase in tropical regions. The new analysis shows, ... degrees a line that runs through central Texas in ...
... heart-healthy, essential omega-3 fatty acid is about to improve ... advance will move biotechnology onto the average consumer,s daily ... deliver positive environmental impacts and increase production to feed ... on Horizon , Recently, the U.S. Food and Drug ...
Cached Biology News:Jaws -- 4 million BC 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 3UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 4New biotech advance to add heart healthy omega-3s to US diet 2
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... South Carolina (PRWEB) May 01, 2015 ... system services, is extremely proud to announce that for ... been named as a winner of a Queen’s Award ... success for the design and manufacture of a unique ... is the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
(Date:4/30/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... commenced an underwritten public offering of its common stock.  ... 30-day option to purchase up to an additional 15 ... the public offering. The offering is subject to market ... whether or when the offering may be completed, or ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) today ... Bulletin Board under,the Symbol LIXT. Commenting on this ... "We believe that being a publicly traded company will,enable ... to us as,a private company. Having access to the ...
... of Cervical ... Cancer Risk, ... it has entered into an agreement to exclusively,license the Human Papillomavirus ... measurement of high-risk HPV types using,DNA-based detection. Quantovir is believed to ...
... MGCD0103,s Orphan Drug, Designation for the Treatment of ... BOULDER, Colo. and MONTREAL, Sept. 24 ,Pharmion Corporation ... MYG) today,announced that the European Medicines Agency (EMEA) ... deacetylase (HDAC),inhibitor, as an Orphan Medicinal Product for ...
Cached Biology Technology:Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 2Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 3Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 4Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 2Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 3Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... The Oxidized LDL Competitive ELISA is ... in the sample competes with a fixed amount ... for the binding of the biotin- labeled specific ... 25 l The Oxidized LDL Competitive Enzyme-Linked ...
Biology Products: